Table 4. Clinical response according to LMR-week 6 for melanoma patients.
Response | Number (N=40, %) | Low LMR-week 6 (N=17, 42.5%) | High LMR-week 6 (N=23, 57.5%) |
---|---|---|---|
CR | 2 (5.0) | 0 (0.0) | 2 (8.7) |
PR | 1 (2.5) | 0 (0.0) | 1 (4.3) |
SD | 16 (40.0) | 9 (52.9) | 7 (30.5) |
PD | 21 (52.5) | 8 (47.1) | 13 (56.5) |
N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.